


Teplinovivint

Cat. No.:	HY-137454
CAS No.:	1428064-91-8
Molecular Formula:	C ₂₅ H ₂₆ N ₆ O ₂
Molecular Weight:	442.51
Target:	Wnt; β -catenin
Pathway:	Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (188.31 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.2598 mL	11.2992 mL	22.5984 mL
				5 mM	0.4520 mL	2.2598 mL	4.5197 mL
				10 mM	0.2260 mL	1.1299 mL	2.2598 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.08 mg/mL (4.70 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: 2.08 mg/mL (4.70 mM); Suspended solution; Need ultrasonic						

BIOLOGICAL ACTIVITY

Description	Teplinovivint is a potent wnt/ β -catenin signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research ^[1] .
IC ₅₀ & Target	Wnt
In Vitro	<p>Teplinovivint (compound 175; 0.0003-10 μM) inhibits Wnt/β-catenin activity in human colorectal cancer cell line (SW480) in a dose-dependent manner (EC₅₀=152.9 nM)^[1].</p> <p>Teplinovivint inhibits SW480 cells (EC₅₀=25 nM) and primary human mesenchymal stem cells (hMSCs; EC₅₀=10.377 μM)^[1].</p> <p>Teplinovivint (5.8, 10.8, 21.7, 41.7, 83.3, 166.6, 333.3, 750 nM) induced the expression of SCXA, TenascinC and Tenomodulin, in a dose-dependent manner with an EC₅₀ between 139-189 nM^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

In Vivo

Teplinovivint (compound 175; 10 mg/ml; once daily for 21 days via topical application) causes amelioration of inflammation as well as tendon degeneration. Teplinovivint results in a decrease of aninflammatory plasma biomarker, KC/GRO in the Collagenase-induced Tendon Injury Model^[1].

Teplinovivint (1 mg/ml with 1% BA) has a T_{max} of 1 hours in plasma^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Vishal DESHMUKH, et al. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors. WO2018075858A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA